Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride - PubMed (original) (raw)
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride
Fuji Yokoi et al. Neuropsychopharmacology. 2002 Aug.
Abstract
Aripiprazole (OPC 14597) is an antipsychotic drug that has high affinity for dopamine D2 and D3 receptors and the dopamine autoreceptor. It is being developed for treatment of patients with schizophrenia. The purpose of this study was to determine whether a dose response following graduated doses of aripiprazole could be quantified and correlated with its occupancy of the D2 and D3 dopamine receptors in the brain of living humans. Dopamine D2 and D3 receptor occupancy in fifteen normal male human brains was measured using positron emission tomography (PET) with [11C]raclopride. PET studies were performed before and after two weeks of administration of aripiprazole. The dopamine D2 receptor occupancy was quantified with two kinetic modeling methods without using a blood input function. Administration of aripiprazole for 14 days resulted in a dose-dependent receptor occupancy between 40 - 95% after the administration of 0.5mg, 1 mg, 2 mg, 10 mg, and 30 mg per day. These results suggest that an adequate occupancy can be obtained, and this may be useful to predict an appropriate therapeutic dose for an individual patient. Interestingly, even at striatal D2 receptor occupancy values above 90%, which occurred with the higher doses, extrapyramidal side effects (EPS) were not observed. This underlines aripiprazole's unique mechanism of action as a partial dopamine receptor agonist, which might become a novel principle in the treatment of schizophrenia.
Similar articles
- Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A. Kegeles LS, et al. Neuropsychopharmacology. 2008 Dec;33(13):3111-25. doi: 10.1038/npp.2008.33. Epub 2008 Apr 16. Neuropsychopharmacology. 2008. PMID: 18418366 - Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Mamo D, et al. Am J Psychiatry. 2007 Sep;164(9):1411-7. doi: 10.1176/appi.ajp.2007.06091479. Am J Psychiatry. 2007. PMID: 17728427 Clinical Trial. - A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G. Mamo D, et al. Am J Psychiatry. 2004 May;161(5):818-25. doi: 10.1176/appi.ajp.161.5.818. Am J Psychiatry. 2004. PMID: 15121646 Clinical Trial. - Mechanism of new antipsychotic medications: occupancy is not just antagonism.
Grunder G, Carlsson A, Wong DF. Grunder G, et al. Arch Gen Psychiatry. 2003 Oct;60(10):974-7. doi: 10.1001/archpsyc.60.10.974. Arch Gen Psychiatry. 2003. PMID: 14557141 Review. - [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Tadori Y, Kikuchi T. Tadori Y, et al. Nihon Shinkei Seishin Yakurigaku Zasshi. 2012 Feb;32(1):9-18. Nihon Shinkei Seishin Yakurigaku Zasshi. 2012. PMID: 22568121 Review. Japanese.
Cited by
- Aripiprazole.
McGavin JK, Goa KL. McGavin JK, et al. CNS Drugs. 2002;16(11):779-86; discussion 787-8. doi: 10.2165/00023210-200216110-00008. CNS Drugs. 2002. PMID: 12383035 Review. - Unique pharmacological profile of aripiprazole as the phasic component buster.
Hamamura T, Harada T. Hamamura T, et al. Psychopharmacology (Berl). 2007 Apr;191(3):741-3. doi: 10.1007/s00213-006-0654-2. Epub 2007 Jan 5. Psychopharmacology (Berl). 2007. PMID: 17205315 Review. - European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.
Roessner V, Eichele H, Stern JS, Skov L, Rizzo R, Debes NM, Nagy P, Cavanna AE, Termine C, Ganos C, Münchau A, Szejko N, Cath D, Müller-Vahl KR, Verdellen C, Hartmann A, Rothenberger A, Hoekstra PJ, Plessen KJ. Roessner V, et al. Eur Child Adolesc Psychiatry. 2022 Mar;31(3):425-441. doi: 10.1007/s00787-021-01899-z. Epub 2021 Nov 10. Eur Child Adolesc Psychiatry. 2022. PMID: 34757514 Free PMC article. Review. - Multiple dynamic interactions from basal ganglia direct and indirect pathways mediate action selection.
Li H, Jin X. Li H, et al. Elife. 2023 Sep 26;12:RP87644. doi: 10.7554/eLife.87644. Elife. 2023. PMID: 37751468 Free PMC article. - Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.
Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. Mauri MC, et al. Clin Pharmacokinet. 2007;46(5):359-88. doi: 10.2165/00003088-200746050-00001. Clin Pharmacokinet. 2007. PMID: 17465637 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical